Uppsala, Sweden – October 31, 2013 - The number of shares and votes in Orexo AB
has changed as a result of the exercise of warrants in connection with the
company’s incentive programs.
Today, the last trading day of the month, there are in total 32,678,941 shares
and votes in the company.
For further information, please contact:
Henrik Juuel, EVP and Chief Financial Officer
Tel: +46 (0)722-20 94 77, E-mail: firstname.lastname@example.org
Orexo is an emerging specialty pharma company with commercial operations in the
United States and R&D in Sweden developing improved treatments using proprietary
drug delivery technology and commercial operations in the United States. The
company is commercializing its proprietary product, Zubsolv® (buprenorphine and
naloxone), for maintenance treatment of opioid dependence, in the United States.
Zubsolv is a novel formulation of buprenorphine and naloxone using Orexo’s
extensive knowledge in sublingual technologies. Orexo has a portfolio of two
approved and revenue generating products currently marketed under license in the
EU and US. Orexo AB, with its headquarters in Sweden, is listed on NASDAQ-OMX
and OTC market in the US (ORXOY). The largest shareholders are Novo A/S and
For information about Orexo please visit www.orexo.com
Orexo AB (publ) discloses the information provided herein pursuant to the
Financial Instruments Trading Act and/or the Securities Markets Act. The
information was submitted for publication at 4:30 pm CET on October 31, 2013.
GlobeNewswire, a NASDAQ OMX company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.